2025-524043-12-00招募中1 期
A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bayer AG
- 入组人数
- 72
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
招募中
不适用
An observational study to verify the safety and effectiveness of treatment using organic iodine + MD(alpha) for patients with advanced cancer (stage 3 or later) using standard and advanced test indicatorsCancerjRCT103026001610
招募中
不适用
An observational study to verify the safety and efficacy of treatment with JWT for patients with advanced cancer (stage 3 or later) using standard and advanced testing indicatorsCancerjRCT103026001110
招募中
1 期
A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.2023-504949-31-00AstraZeneca AB37
招募中
1 期
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers2024-518889-27-00SmartDyeLivery GmbH48